Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUTASTERIDE vs NALBUPHINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of type II and type I 5α-reductase isoenzymes, blocking conversion of testosterone to dihydrotestosterone (DHT) in prostate, hair follicles, and other tissues.
Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.
FDA: Treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate,FDA: Reduce risk of acute urinary retention,FDA: Reduce need for BPH-related surgery,Off-label: Male androgenetic alopecia
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
0.5 mg orally once daily.
10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.
Terminal half-life approximately 3-4 weeks (21-35 days) in young adults; 5-6 weeks in elderly; supports once-daily dosing due to slow elimination.
Terminal elimination half-life is approximately 5 hours (range 3-6 hours) in adults; prolonged in hepatic impairment.
Extensively metabolized in liver via CYP3A4 and CYP1A2; minor metabolism by CYP2C8, CYP2C9, CYP2C19, and CYP2D6.
Hepatic via glucuronidation; primarily metabolized by UGT2B7; minor CYP450 involvement.
Primarily fecal (70%) as metabolites; renal excretion accounts for <5% unchanged drug.
Primarily hepatic metabolism (CYP3A4 and glucuronidation); <5% excreted unchanged in urine; ~70% excreted as metabolites in urine, ~30% in feces.
>99% bound to albumin and alpha-1 acid glycoprotein; high affinity.
Approximately 50% bound to plasma proteins, primarily albumin.
Approximately 300-500 L (3-5 L/kg), indicating extensive tissue distribution, particularly to prostate and seminal vesicles.
Approximately 2.6 L/kg (range 1.6-3.8 L/kg); indicates extensive tissue distribution.
Oral: Approximately 60% (range 40-80%) with food; not administered parenterally.
Intramuscular and subcutaneous: approximately 80%; oral: low (extensive first-pass metabolism, <20% oral bioavailability).
No dose adjustment required for renal impairment (including dialysis).
Cr Cl 30-50 m L/min: administer 75% of normal dose; Cr Cl 10-29 m L/min: administer 50% of normal dose; Cr Cl <10 m L/min: avoid use or use with extreme caution.
Contraindicated in Child-Pugh Class C; use with caution in mild to moderate impairment (Child-Pugh A/B) with no specific dose adjustment established.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: reduce dose by 50% or avoid.
Not indicated in pediatric patients; safety and efficacy not established.
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
No specific dose adjustment required; monitor for adverse effects (e.g., dizziness, orthostatic hypotension) due to age-related comorbidities.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
No FDA black box warning.
Risk of respiratory depression, abuse, misuse, and addiction; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of high-grade prostate cancer in men aged 50-79 with elevated PSA and previous negative biopsy (see PLCO trial),Increased risk of sexual adverse events (impotence, decreased libido, ejaculation disorders) that may persist after discontinuation,Elevated PSA levels: use caution when interpreting PSA values; establish new baseline after 6 months of treatment
Respiratory depression; abuse potential; neonatal opioid withdrawal syndrome; adrenal insufficiency; severe hypotension; head injury and increased intracranial pressure; severe hepatic or renal impairment.
Women of childbearing potential (pregnancy category X; risk of fetal harm due to inhibition of 5α-reductase),History of hypersensitivity to dutasteride or other 5α-reductase inhibitors,Pediatric patients
Hypersensitivity to nalbuphine or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; suspected or known gastrointestinal obstruction; use of MAOIs within 14 days.
No clinically significant food interactions. May be taken with or without food. Grapefruit juice does not affect dutasteride levels to a clinically relevant extent.
No specific food interactions. Avoid grapefruit juice as it may theoretically increase nalbuphine levels (CYP3A4 substrate, though major metabolism via glucuronidation). Maintain adequate hydration to prevent constipation.
Dutasteride is contraindicated in pregnancy. It is a 5α-reductase inhibitor that can inhibit the conversion of testosterone to dihydrotestosterone (DHT), potentially causing abnormal development of external genitalia in male fetuses. Risk extends throughout all trimesters due to potential disruption of androgen-mediated development in male fetuses during the first trimester and cumulative effects from drug accumulation in adipose tissue. No adequate human studies exist; animal studies show teratogenicity in male offspring at clinically relevant doses.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if potential benefit justifies risk. In first trimester, avoid unless necessary. Second and third trimesters: risk of neonatal respiratory depression, withdrawal if chronic use. Near term: may prolong labor and cause neonatal respiratory depression.
No data on dutasteride in human milk. M/P ratio unknown. Dutasteride is highly lipophilic and likely excreted in breast milk. Because of potential adverse effects on the nursing infant (e.g., interference with androgen-mediated development in male infants), breastfeeding is contraindicated during therapy and for at least 6 months after the last dose due to long half-life (approximately 5 weeks).
Excreted in breast milk in small amounts; M/P ratio approximately 0.47-1.5. Limited data; caution recommended. Monitor infant for sedation and respiratory depression. Benefits of breastfeeding should outweigh risks.
No dose adjustment studies in pregnancy because dutasteride is contraindicated. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) could affect dutasteride levels, but no adjustments are recommended as drug should not be used. If inadvertently used, discontinue immediately and monitor for adverse effects.
No specific dose adjustment recommended for pregnancy, but pharmacokinetics may be altered due to increased volume of distribution and clearance. Dosing should be on an individual basis, titrated to effect. Use lowest effective dose and shortest duration. During labor, doses should be reduced due to potential for respiratory depression in neonate.
Monitor PSA levels cautiously, as dutasteride reduces serum PSA by approximately 50% after 6 months; double the PSA value for comparison to untreated men. Do not handle crushed or broken capsules if pregnant or planning pregnancy, as absorption through skin may cause fetal harm. Assess for signs of high-grade prostate cancer before initiating therapy, as dutasteride may increase the risk of Gleason 8-10 tumors. Onset of symptom relief may take 3-6 months; do not discontinue prematurely. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) as they increase dutasteride exposure.
Nalbuphine is a mixed agonist-antagonist opioid with ceiling effect on respiratory depression; less abuse liability than morphine. Useful for opioid-induced pruritus (e.g., with morphine) at low doses (0.1 mg/kg IV). May precipitate withdrawal in opioid-dependent patients. Avoid in opioid-tolerant patients on full agonists. Metabolized by liver; adjust dose in hepatic impairment. Not a controlled substance (US), but report to regulatory authorities as required.
Take exactly as prescribed; do not stop or change dose without consulting your doctor.,Swallow the capsule whole; do not chew or open it.,It may take 3 to 6 months to see improvement in symptoms.,Avoid handling leaking or crushed capsules if you are a woman who is or may become pregnant; wash area immediately with soap and water if skin contact occurs.,Do not donate blood for at least 6 months after your last dose to prevent exposure to a pregnant woman.,Report any breast lumps, pain, or nipple discharge promptly.,You will need regular blood tests for PSA level monitoring; inform your doctor that you are taking dutasteride.,Dutasteride can decrease sperm count and may affect fertility; discuss this with your doctor if planning to father a child.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how nalbuphine affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, coma, or death.,Do not stop suddenly after prolonged use; withdrawal symptoms may occur but are generally milder than with full agonists.,Report any signs of allergic reaction (rash, hives, swelling) or difficulty breathing immediately.,If you have been taking other opioids, inform your doctor to avoid withdrawal symptoms.,Store at room temperature away from heat, light, and moisture; keep out of reach of children.
"Dutasteride, a 5α-reductase inhibitor, may inhibit cytochrome P450 enzymes, particularly CYP3A4, which is involved in the metabolism of sulfisoxazole. This inhibition can lead to decreased clearance of sulfisoxazole, resulting in elevated plasma concentrations. Increased sulfisoxazole levels may potentiate its adverse effects, including hypersensitivity reactions, crystalluria, and hematologic toxicity such as agranulocytosis."
"Concomitant use of dutasteride, a 5α-reductase inhibitor, with nelfinavir, a protease inhibitor and potent CYP3A4 inhibitor, is predicted to increase the serum concentration of nelfinavir. This occurs because dutasteride may inhibit the metabolism of nelfinavir via competition for CYP3A4, leading to elevated nelfinavir levels and an increased risk of adverse effects such as gastrointestinal disturbances, hepatotoxicity, and metabolic complications. Clinical monitoring for toxicity and dose adjustments are warranted."
"Dutasteride, a 5α-reductase inhibitor, is metabolized primarily by CYP3A4 and to a lesser extent by CYP2D6. Itraconazole is a potent inhibitor of CYP3A4 and also inhibits P-glycoprotein. Coadministration leads to significantly increased serum concentrations of dutasteride, raising the risk of adverse effects such as gynecomastia, sexual dysfunction, and depression. The effect on itraconazole levels is minimal and clinically irrelevant."
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUTASTERIDE vs NALBUPHINE HYDROCHLORIDE, answered by our medical review team.
DUTASTERIDE is a 5-alpha Reductase Inhibitor that works by Competitive inhibitor of type II and type I 5α-reductase isoenzymes, blocking conversion of testosterone to dihydrotestosterone (DHT) in prostate, hair follicles, and other tissues.. NALBUPHINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUTASTERIDE and NALBUPHINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUTASTERIDE is: 0.5 mg orally once daily.. The standard adult dose of NALBUPHINE HYDROCHLORIDE is: 10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUTASTERIDE and NALBUPHINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUTASTERIDE is classified as Category D/X. Dutasteride is contraindicated in pregnancy. It is a 5α-reductase inhibitor that can inhibit the conversion of testosterone to dihydrotestosterone (DHT), potentially causing abnorm. NALBUPHINE HYDROCHLORIDE is classified as Category A/B. Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if pot. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.